PMID- 29716593 OWN - NLM STAT- MEDLINE DCOM- 20190730 LR - 20220409 IS - 1476-4598 (Electronic) IS - 1476-4598 (Linking) VI - 17 IP - 1 DP - 2018 May 1 TI - RNA-Seq profiling of circular RNAs in human laryngeal squamous cell carcinomas. PG - 86 LID - 10.1186/s12943-018-0833-x [doi] LID - 86 AB - Abnormal expression of non-coding circular RNAs (circRNAs) have been reported in many types of tumors. circRNA have been suggested to be an ideal candidate biomarker for diagnostic and therapeutic implications in cancers. The aim of this study was to assess the circRNA expression profile of laryngeal squamous cell carcinomas (LSCC). The biopsy samples from patients with LSCC were obtained intra-operatively. The circRNA expression was performed using secondary sequencing. Among 10 patients with LSCC, 2 were well differentiated, 3 were moderately differentiated and 5 were adjunctive samples with normal and LSCC tissues. A total of 21,444 distinct circRNA candidates were detected. Among them, we defined the statistical criteria for selecting aberrant-expressed circRNA using a q-value of < 0.001 with a fold change of > 2.0 or < 0.5. A total of 29 circRNA were upregulated and 19 circRNA were downregulated significantly in the LSCC tissues. The intersection of these dysregulated circRNAs of normal-well differentiated set and normal-moderately differentiated set was then assessed to narrow the upregulated and downregulated circRNAs down to 18 and 5 respectively. Furthermore, an association of the circRNA-miRNA-mRNA was investigated, showing that 20 dysregulated circRNA successfully predicted an interaction with several cancer-related miRNAs. Finally, a further KEGG analysis showed that PPAR, Axon guidance, Wnt and Cell cycle signaling pathway were key putative pathways in the process of LSCC. hsa_circ:chr20:31876585-31,897,648 was found to be able to differentiate most of LSCC from the matching normal tissues. This observational study demonstrated dysregulation of circRNA in LSCC, which may have an impact on development of potential biomarkers in this disease. Validation of down-regulation of hsa_circ:chr20:31876585-31,897,648 in LSCC compared to each adjunctive tissue by Q-RT-PCR, indicating that hsa_circ:chr20:31876585-31,897,648 may be a novel promising tumor suppresser in LSCC. FAU - Lu, Cheng AU - Lu C AUID- ORCID: 0000-0002-1495-8522 AD - Department of Otolaryngology, Head Neck Surgery, Beijing Friendship Hospital, Capital Medical University, 95th Yong'an Road, Xicheng District, Beijing, 100050, China. FAU - Shi, Xi AU - Shi X AD - The Institute of Audiology and Speech Science of Xuzhou Medical Collage, Xuzhou, 221004, China. FAU - Wang, Amanda Y AU - Wang AY AD - The renal and Metabolic Division, The George Institute for Global Health, UNSW, Australia; Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW, 2109, Australia. awang@georgeinstitute.org.au. FAU - Tao, Yuan AU - Tao Y AD - Department of Otolaryngology, Peking University Shenzhen Hospital, Shenzhen, 518036, China. FAU - Wang, Zhenxiao AU - Wang Z AD - Department of Otolaryngology, Head Neck Surgery, Beijing Friendship Hospital, Capital Medical University, 95th Yong'an Road, Xicheng District, Beijing, 100050, China. FAU - Huang, Chaoping AU - Huang C AD - Department of Otolaryngology, Head Neck Surgery, Beijing Friendship Hospital, Capital Medical University, 95th Yong'an Road, Xicheng District, Beijing, 100050, China. FAU - Qiao, Yuehua AU - Qiao Y AD - The Institute of Audiology and Speech Science of Xuzhou Medical Collage, Xuzhou, 221004, China. FAU - Hu, Hongyi AU - Hu H AD - Department of Otolaryngology, Peking University Shenzhen Hospital, Shenzhen, 518036, China. hyihu@sina.com. FAU - Liu, Liangfa AU - Liu L AD - Department of Otolaryngology, Head Neck Surgery, Beijing Friendship Hospital, Capital Medical University, 95th Yong'an Road, Xicheng District, Beijing, 100050, China. liuliangfa301@163.com. LA - eng PT - Letter PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20180501 PL - England TA - Mol Cancer JT - Molecular cancer JID - 101147698 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) RN - 0 (RNA, Circular) RN - 0 (RNA, Messenger) RN - 63231-63-0 (RNA) MH - Biomarkers, Tumor/genetics MH - Carcinoma, Squamous Cell/*genetics MH - Cell Line, Tumor MH - Gene Expression Profiling/*methods MH - Gene Expression Regulation, Neoplastic MH - Gene Regulatory Networks MH - High-Throughput Nucleotide Sequencing MH - Humans MH - Laryngeal Neoplasms/*genetics MH - MicroRNAs/genetics MH - RNA/*genetics MH - RNA, Circular MH - RNA, Messenger/genetics MH - Sequence Analysis, RNA PMC - PMC5930968 OTO - NOTNLM OT - Circular RNAs (circRNAs) OT - Laryngeal squamous cell carcinomas (LSCC) OT - RNA-sequencing (RNA-Seq) COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The human cancer tissues used in this study were approved by the institute ethical committee of Beijing Friendship Hospital, Capital Medical University. (Approval Number: YYBB-B01-01-R02-V4.0 / 20,170,605). CONSENT FOR PUBLICATION: We have received consents from individual patients who have participated in this study. The consent forms will be provided upon request. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/05/03 06:00 MHDA- 2019/07/31 06:00 PMCR- 2018/05/01 CRDT- 2018/05/03 06:00 PHST- 2018/01/23 00:00 [received] PHST- 2018/04/10 00:00 [accepted] PHST- 2018/05/03 06:00 [entrez] PHST- 2018/05/03 06:00 [pubmed] PHST- 2019/07/31 06:00 [medline] PHST- 2018/05/01 00:00 [pmc-release] AID - 10.1186/s12943-018-0833-x [pii] AID - 833 [pii] AID - 10.1186/s12943-018-0833-x [doi] PST - epublish SO - Mol Cancer. 2018 May 1;17(1):86. doi: 10.1186/s12943-018-0833-x.